掘金港股生物科技核心资产 广发恒生生物科技ETF正在发售

Core Insights - The biotechnology industry is rapidly developing and is a key direction for global technological revolution and industrial upgrading, with innovative drugs being a core engine of the industry [1] - The Hong Kong stock market is becoming an important platform for financing and value discovery for biotechnology companies, driven by favorable policies, active capital, and technological breakthroughs [1] - China is transitioning from "broad innovation" to "differentiated innovation and international development," with a significant increase in the approval and market entry of innovative drugs [2] Industry Overview - The biotechnology sector is a strategic emerging industry based on life sciences, encompassing innovative drugs, gene technology, and cell therapy, supported by a threefold driving force of policy benefits, capital support, and technological advancements [1] - The demand for treatment of diseases such as tumors and cardiovascular conditions is expected to grow due to an aging population and increased healthcare spending, providing substantial growth opportunities for the industry [2] Market Trends - The global mergers and acquisitions (M&A) in the pharmaceutical and biotechnology sectors are expected to reach a historical high by 2026, with significant activity in the Hong Kong stock market [1] - In 2025, China is projected to have 76 innovative drugs approved for market entry, with over 80% being domestic innovations, and a record-breaking total of over $130 billion in licensing-out transactions [2] Investment Opportunities - The Hang Seng Biotechnology Index (HSBIO.HI) highlights the investment value of high-purity and scarce biotechnology companies, with a significant focus on cutting-edge technologies [3] - The HSBIO index has shown a remarkable performance, with an increase of 82.2% over the past year, outperforming similar indices in the healthcare sector [3] - The launch of the Guangfa Hang Seng Biotechnology ETF aims to facilitate efficient investment in core biotechnology assets in Hong Kong, with advantages such as T+0 trading and low fees [3][4]